Xov xwm kev lag luam
Lub Sijhawm Ua Tau Zoo ntawm CD19 CAR T-Cell Therapy hauv Kev Kho Mob Relapsed/Refractory Acute Lymphoblastic Leukemia
Ib txoj kev tshawb nrhiav pom pom qhov ua tiav ntev ntawm CD19 CAR T-cell txoj kev kho mob hauv kev kho cov neeg mob rov qab / refractory mob lymphoblastic leukemia (TAG NRHO) tom qab allogeneic hematopoietic qia cell transplantation, muab kev cia siab tshiab hauv hematology.
Kev Tshaj Tawm Ua Ntej Hauv Ntuj Killer (NK) Cells Tshaj 50 Xyoo
Tshaj li tsib xyoos dhau los, kev tshawb fawb ntawm Natural Killer (NK) hlwb tau hloov pauv peb txoj kev nkag siab ntawm kev tiv thaiv kab mob hauv lub cev, muab cov lus cog tseg tshiab rau kev kho mob qog noj ntshav thiab kab mob.
Kev Kho Mob Hauv Pediatric Autoimmune Disease: CAR-T Cell Therapy Kho Lupus Patient
Ib txoj kev tshawb fawb pioneering ntawm Erlangen University Tsev Kho Mob tau ua tiav kho tus ntxhais hnub nyoog 16 xyoo uas muaj mob hnyav lupus erythematosus (SLE) siv CAR-T cell therapy. Qhov no yog thawj zaug siv qhov kev kho mob rau menyuam yaus lupus, muab kev cia siab tshiab rau cov menyuam yaus uas muaj kab mob autoimmune.
Txhim kho qhov ua tau zoo ntawm PROTAC: Kev Tshawb Fawb Txog Kev Tshawb Fawb
Ib txoj kev tshawb fawb tsis ntev los no hauv Nature Communications nthuav tawm cov kev nkag siab tseem ceeb rau hauv txoj hauv kev taw qhia qhov tseeb uas hloov kho cov txiaj ntsig ntawm cov phiaj xwm degradation siv PROTACs. Qhov kev tshawb pom no tuaj yeem ua rau txoj hauv kev rau kev kho mob zoo dua rau mob qog noj ntshav thiab lwm yam kab mob.
Txhawb Kev Noj Qab Haus Huv thiab Rov Qab Los: Kev Saib Xyuas Txhua Hnub rau Cov Neeg Mob Leukemia
Ua kom muaj kev nyab xeeb thiab xis nyob hauv kev kho mob rau cov neeg mob leukemia suav nrog kev saib xyuas txhua hnub, suav nrog kev huv huv ib puag ncig, kev tu tus kheej, khoom noj khoom haus, thiab kev tawm dag zog kom tsim nyog. Phau ntawv qhia no muab cov lus qhia tseem ceeb rau kev saib xyuas txhua hnub kom muaj txiaj ntsig zoo.
Groundbreaking Results of CD7-Targeted CAR-T Therapy for T-ALL thiab T-LBL
Ib txoj kev tshawb fawb tsis ntev los no qhia txog cov txiaj ntsig tau zoo ntawm CD7-targeted chimeric antigen receptor (CAR) T cell therapy hauv kev kho cov neeg mob rov qab los yog refractory T-cell mob lymphoblastic leukemia (T-ALL) thiab T-cell lymphoblastic lymphoma (T-LBL).
Kev pab them nqi ntawm 2024 ASH Lub Rooj Sib Tham Txhua Xyoo thiab Kev Tshaj Tawm
Lub 66th Lub Rooj Sib Tham Txhua Xyoo ntawm American Society of Hematology (ASH) yuav muaj nyob rau lub Kaum Ob Hlis 7-10, 2024, ntawm San Diego Convention Center, qhia txog kev tshawb fawb thiab kev nce qib hauv hematology.
Kev Cia Siab Tshiab hauv Kev Kho Mob Cancer: TILs Therapy Emerges as the Next Frontier
Txawm hais tias muaj kev sib tw tsis tu ncua hauv kev lag luam thiab kev lag luam, CAR-T txoj kev kho cov kev txwv tau raug hais los ntawm kev cog lus tshiab: Tumor-Infiltrating Lymphocyte (TIL) therapy. Qhov kev tawg no tau tshaj tawm lub sijhawm tshiab hauv kev tawm tsam cov qog nqaij hlav.
Puas yog Cellular Therapies yav tom ntej ntawm autoimmune Disease?
Kev kho mob rau cov qog nqaij hlav kuj tseem tuaj yeem kho thiab rov kho lub cev tiv thaiv kab mob kom muab kev kho mob mus ntev lossis tej zaum txawm kho qee yam kab mob autoimmune.
